AI THERAPEUTICS
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefits for LAM patients. AI Therapeutics develops drugs for rare diseases and cancer. LAM ... takes advantage of the inflection point in biological understanding and computer science, leveraging big data from NextGen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
AI THERAPEUTICS
Industry:
Artificial Intelligence Biotechnology Genetics Medical Therapeutics
Founded:
2013-01-01
Address:
Guilford, Connecticut, United States
Country:
United States
Website Url:
http://www.ai-therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(203)458-7100
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
Amazon GoDaddy DNS Facebook Sharer Pinterest GoDaddy AWS Global Accelerator GoDaddy Email Amazon Frankfurt Region Reddit
Current Advisors List
Current Employees Featured
Founder
Investors List
BioVenture
BioVenture investment in Series C - AI Therapeutics
4Catalyzer
4Catalyzer investment in Seed Round - AI Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-16 | AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer |
Official Site Inspections
http://www.ai-therapeutics.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "AI Therapeutics"
OrphAI Therapeutics
GUILFORD,CT, September 28, 2023 — AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has …See details»
AI Therapeutics Announces Name Change to OrphAI
Sep 28, 2023 · As part of the name change, the company is launching a new website at “OrphAI-Therapeutics.com”. The new name reflects the company’s evolution into a company with …See details»
OrphAI Therapeutics - Crunchbase Company Profile
OrphAI Therapeutics formerly known as AI Therapeutics develops drugs for rare diseases and cancer. View contacts for OrphAI Therapeutics to access new leads and connect with decision-makers.See details»
AI Therapeutics Announces Name Change to OrphAI Therapeutics
Sep 28, 2023 · As part of the name change, the company is launching a new website at “OrphAI-Therapeutics.com”. The new name reflects the company’s evolution into a company with …See details»
OrphAI Therapeutics
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced …See details»
OrphAI Therapeutics
The company is building out an expansive rare disease pipeline with the help of its Guardian Angel TM Platform, a suite of artificial intelligence tools that use deep learning to understand …See details»
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of ...
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced …See details»
Artificial intelligence foundation for therapeutic science
Sep 21, 2022 · Artificial intelligence (AI) is poised to transform therapeutic science. Therapeutics Data Commons is an initiative to access and evaluate AI capability across therapeutic …See details»
AI Therapeutics' narrowed ambitions for ALS drug pay …
Apr 5, 2023 · AI announced Wednesday that AIT-101—formerly LAM-002A— hit the primary endpoints of safety, tolerability and successful drug deliverability and that critical biomarkers are trending in the...See details»
These Six Biotechs are Winning the Race to Get AI …
Aug 16, 2022 · Artificial intelligence (AI) has the potential to improve many areas of medicine, with drug development as a key focus. Many companies are now working to apply the power of AI to design better drugs, but six companies are …See details»
AI Therapeutics Announces the Acquisition of Novel Cancer Drug ...
GUILFORD, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, …See details»
Inside the nascent industry of AI-designed drugs - Nature
Jun 1, 2023 · Artificial intelligence tools are beginning to upend the drug discovery pipeline, with several new compounds entering clinical trials. Drug discovery is expensive, inefficient, and …See details»
OrphAI Therapeutics
GUILFORD,CT, April 5,2023 — AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today positive results from a …See details»
New regulatory thinking is needed for AI-based personalised drug …
Jan 30, 2024 · Now, a number of approaches have been proposed for the personalisation of drug and cell therapies with AI applied to therapy design, planning and delivery at the patient’s …See details»
AI Therapeutics Announces Initiation of a Phase II Clinical
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced …See details»
AI in small-molecule drug discovery: a coming wave? - Nature
Companies were identified based on the reported central role of artificial intelligence (AI) technologies in their strategy for small-molecule drug discovery and their development of their …See details»
AAIH
Through the thoughtful and responsible application of AI in the discovery and development of new therapies, AI has the power to improve patients’ lives while creating more efficient, sustainable …See details»
Halozyme Therapeutics to Host Presentations at Investor …
1 day ago · SAN DIEGO, Nov. 27, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that members of its executive leadership team will …See details»
AI Therapeutics Announces Positive Results from Phase 2a …
GUILFORD, Conn., April 05, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced …See details»
News - OrphAI Therapeutics
Feb 15, 2024 · AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)See details»